It is estimated that approximately 40% to 50% of patients with hormone receptor-positive/HER2− breast cancer have aberrant activation of PIK3CA (encoding the p110α isoform of PI3K) (11, 12), which is closely correlated with ET resistance. This evidence concerns the gene PIK3CA and breast carcinoma.